Claims for Patent: 9,168,234

Summary for Patent: 9,168,234

Title:	Bupropion as a modulator of drug activity
Abstract:	This disclosure relates to methods administering bupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion or a prodrug of bupropion are also disclosed.
Inventor(s):	Tabuteau; Herriot (New York, NY)
Assignee:	ANTECIP BIOVENTURES II LLC (New York, NY)
Application Number:	14/604,397
Patent Claims:	1. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering about 150 mg per day to about 500 mg per day of bupropion with dextromethorphan to the human being for at least eight consecutive days, wherein bupropion and dextromethorphan are administered once or twice a day, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, and wherein on the eighth day, the co-administration results in an AUC.sub.0-12 of dextromethorphan that is at least about 20 times the AUC.sub.0-12 that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days. 2. The method of claim 1, wherein the human being is an extensive metabolizer of dextromethorphan. 3. The method of claim 2, wherein the AUC.sub.0-12 of dextromethorphan on Day 8 is at least about 700 nghr/mL. 4. The method of claim 2, wherein the AUC.sub.0-24 of dextromethorphan on Day 8 is at least about 1000 nghr/mL. 5. The method of claim 2, wherein the AUC.sub.0-inf of dextromethorphan on Day 8 is at least about 2000 nghr/mL. 6. The method of claim 2, wherein the AUC.sub.0-inf of dextromethorphan on Day 8 is at least about 3000 nghr/mL. 7. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering about 150 mg per day to about 500 mg per day of bupropion with dextromethorphan to the human being for at least eight consecutive days, wherein bupropion and dextromethorphan are administered once or twice a day, wherein the human being is in need of treatment with increased plasma levels of dextromethorphan, and wherein on the eighth day, the co-administration results in a C.sub.max of dextromethorphan that is at least about 20 times the C.sub.max that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days. 8. The method of claim 7, wherein the human being is an extensive metabolizer of dextromethorphan. 9. The method of claim 8, wherein the C.sub.max of dextromethorphan on Day 8 is at least about 80 ng/mL. 10. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering about 150 mg per day to about 500 mg per day of bupropion with dextromethorphan to the human being for at least eight consecutive days, wherein bupropion and dextromethorphan are administered once or twice a day, wherein the human being is in need of treatment with increased plasma levels of dextromethorphan, and wherein on the eighth day, the co-administration results in a C.sub.avg of dextromethorphan over the period between two separate and consecutive administrations of dextromethorphan that is at least about 20 times the C.sub.avg that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days. 11. The method of claim 10, wherein the bupropion is administered in an amount that results in a C.sub.avg of dextromethorphan, over the period between two separate and consecutive administrations of dextromethorphan, that is at least about 60 ng/mL. 12. The method of claim 10, wherein the human being is an extensive metabolizer of dextromethorphan.